{"article":{"id":53183,"heading":"Peg Intron and Interferon","author":"Heppers Helper","created":"2003-04-25 07:11:49","modified":"2003-04-25 07:11:49","last_modified":"Fri, 25 Apr 2003 15:11:49","article":"<strong>Considering Peg Intron and Interferon<\/strong>\r\n<br>\r\n <p>I have been trying for years to \r\n                        expose the truth behind PEG-Intron therapy, its horrible \r\n                        side effects, its ineffectiveness, and the real reason \r\n                        the drug manufacturer altered Interferon to create it. \r\n                        I have been doing this partly by relaying to you what \r\n                        I have read and researched over the years, but mostly \r\n                        by relating to you my personal experience with the drug, \r\n                        and the experiences of my friends and customers.\r\n                      <\/p><p> <strong>Now I have something more.<\/strong><br>\r\n                        Following is the actual clinical review of Schering's \r\n                        application for PEG-Intron to The Center of Biologics \r\n                        Evaluation and Research (<em>CBER<\/em>), the division \r\n                        of the FDA that regulates these types of drugs. In other \r\n                        words, it is the highest authority's (<em>CBER<\/em>) review \r\n                        of PEG-Intron, as studied by the very people who most \r\n                        wanted it to be approved (<em>Schering<\/em>). It reads \r\n                        like an admission, an admission that the drug is neither \r\n                        safe nor effective, but \"hey, it's all we've got\". \r\n                        It may shock you. It may only confirm what you already \r\n                        know. <\/p>\r\n                      <p> The review is here for you in its entirety - but it \r\n                        is long and technical. If you would like to go directly \r\n                        to the points that I think are most interesting, I have \r\n                        outlined them (<em>along with each of their page number\/paragraph<\/em>) \r\n                        for you below under the following four categories: <\/p>\r\n<p><strong>&sect; \r\n                              PEG-Intron is the Same Drug as Interferon Only Worse<\/strong><\/p>\r\n                            <p><strong>&sect; \r\n                              This Study is Flawed<\/strong><\/p>\r\n                            <p><strong>&sect; \r\n                              PEG-Intron is NOT Safe<\/strong><\/p>\r\n                            <p><strong>&sect; \r\n                              PEG-Intron is NOT Effective<\/strong><\/p>\r\n                   <hr size=\"1\" width=\"100%\" noshade align=\"left\">\r\n                      <strong>PEG-INTRON \r\n                        IS THE SAME DRUG AS INTERFERON<\/strong> \r\n                      <p align=\"center\">You need only read one paragraph into \r\n                        the study to learn that PEG-Intron is the same drug as \r\n                        Interferon, only modified to stay in your system longer \r\n                        <strong>&nbsp;(Thereby killing you more \r\n                        consistently)&nbsp;<\/strong>.<\/p>\r\n<p><strong>\"<\/strong>PEG-lntronTM, \r\n                              peg-interferon alfa-2b, is a covalent conjugate \r\n                              of recombinant  interferon \r\n                              alfa-2b with monomethoxy polyethylene glycol product. \r\n                              The biological activity of peg-interferon alfa-2b \r\n                              is derived from its interferon alfa-2b moiety.<strong>\"<\/strong> \r\n                              <strong>(3\/1)<\/strong><\/p>\r\n                      <p> Monomethoxy polyethylene glycol (mPEG) prolongs circulation \r\n                        time, delaying clearance of the drug and therefore reducing \r\n                        dosing frequency. You may believe that this feature was \r\n                        reason enough to reformulate Interferon, or you may believe \r\n                        that the reformulation had more to do with the fact that \r\n                        Shering Plough's patent for Interferon ran out, their \r\n                        market share dropped from 2.4 billion down to 700 million \r\n                        and they needed a new drug to re-capture market share.<\/p>\r\n                      <p> Regarding the safety of PEG-Intron, the researchers \r\n                        concluded again and again that the types of \"adverse \r\n                        events\" reported were similar to those associated \r\n                        with Interferon. They concluded, not that PEG-Intron is \r\n                        safe, but rather that it is about as safe as Interferon \r\n                        in terms of the kinds of side effects people experienced.<\/p>\r\n<p><strong>\"<\/strong>The \r\n                              safety profile of peg-interferon in this study was \r\n                              consistent with that of alpha-interferons.<strong>\"<br>\r\n                              (6\/3)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>Peg-interferon \r\n                              alfa-2b administered for 24 weeks to subjects with \r\n                              chronic hepatitis C had an adverse event profile \r\n                              similar to that observed with interferon alfa-2b.<strong>\" \r\n                              (9\/2)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>Adverse \r\n                              events moderate to mild in severity typical of Interferon \r\n                              toxicity were observed.<strong>\"<br>\r\n                              (9\/7)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>Peg-interferon \r\n                              alfa induced serious and non-serious adverse events \r\n                              typical of interferon alfa.<strong>\"<br>\r\n                              (10\/4)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>Mild \r\n                              to moderate adverse events were observed and were \r\n                              consistent with those induced by alfa interferon.<strong>\"<br>\r\n                              (10\/7)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>The \r\n                              types of adverse events were similar between peg-interferon \r\n                              and interferon groups.<strong>\"<br>\r\n                              (40\/10)<\/strong><\/p>\r\n\r\n<p align=\"center\"><strong>ONLY WORSE<\/strong><\/p>\r\n                      <p>However, in terms of the number of adverse events, or \r\n                        the frequency of adverse events, they determined that \r\n                        PEG-Intron was actually worse.<\/p>\r\n\r\n<p><strong>\"<\/strong>Patients receiving peg-interferon \r\n                              appeared to experience a greater number of adverse \r\n                              events<br>\r\n                              (<em>e.g. injection site reaction, fever, rigors, \r\n                              nausea<\/em>) compared to patients receiving interferon.<\/p>\r\n                            <p>The number of adverse events in all body systems \r\n                              in general was higher in patients receiving the \r\n                              higher peg-interferon dosages.<strong>\"<br>\r\n                              (40\/8,9)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>The percentage of patients \r\n                              withdrawn from treatment was similar (<em>around \r\n                              20%<\/em>) in the four treatment groups (<em>see \r\n                              Table 5<\/em>). In the 1 .O pg\/kg peg-interferon \r\n                              group the percentage of withdrawals due to adverse \r\n                              events appeared to be higher (<em>12%<\/em>) and \r\n                              the percentage of withdrawals due to treatment failure \r\n                              appeared to be lower (<em>cl %<\/em>) compared to \r\n                              the interferon-treated group (<em>6% and 5% respectively<\/em>).<strong>\"<br>\r\n                              (18\/1)<\/strong><\/p>\r\n\r\n<p>***Please \r\n                              see Table 5 on page 18, titled \"Number of Patients \r\n                              Withdrawn during the Treatment Period and Reason \r\n                              for Withdrawal\". It shows that between 9% and \r\n                              12% of participants were actually withdrawn from \r\n                              the treatment due to adverse events (6% of the Interferon \r\n                              group were withdrawn). ***<\/p>\r\n\r\n<p align=\"center\"><strong>THIS \r\n                        STUDY IS FLAWED<\/strong><\/p>\r\n                      <p align=\"left\">The researchers admit to a very low response \r\n                        rate to PEG-Intron therapy (<em>anywhere from 5% to 27% \r\n                        depending on the study<\/em>). But even these numbers are \r\n                        overestimated due to the way they defined and measured \r\n                        patient response; the ways in which the patient's response \r\n                        was defined and measured were not sufficient to establish \r\n                        the efficacy of peg-interferon.<\/p>\r\n\r\n<p><strong>\"<\/strong>Virologic \r\n                              response was defined as undetectable serum HCV-RNA \r\n                              (cl00 copies\/ml of serum) \r\n                              at any time during treatment or follow-up.<strong>\"<br>\r\n                              (8\/2)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>Patients \r\n                              were considered to have responded to treatment if \r\n                              they were HCV-RNA positive at baseline and were \r\n                              HCV-RNA negative at the end of treatment (24 weeks) \r\n                              and at follow-up (4 weeks \r\n                              post-treatment).<strong>\"<br>\r\n                              (8\/6)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>Response \r\n                              to treatment was defined as loss of serum HCV-RNA \r\n                              (cl00 copies\/ml) and normalization of ALT measured \r\n                              at one time point during \r\n                              treatment (24 weeks of treatment) and at \r\n                              one time point during follow up (6 months post-treatment).<strong>\"<br>\r\n                              (12\/4)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>There \r\n                              was no requirement for minimum duration of loss \r\n                              of HCV RNA detection.<strong>\"<br>\r\n                              (20\/4)<\/strong><\/p>\r\n\r\n <p>And they also admit that even these \"responders\" \r\n                        to treatment are not necessarily cured.<\/p>\r\n\r\n<p><strong>\"<\/strong>Long term studies are \r\n                              needed to determine what proportion of treatment \r\n                              responders achieve cure (viral eradication).<strong>\"<br>\r\n                              (21\/3)<\/strong><\/p>\r\n\r\n <p align=\"center\">PEG-INTRON \r\n                        IS NOT SAFE<\/p>\r\n                      <p align=\"center\"><strong>The following were taken from \r\n                        the results of<br>\r\n                        the Phase 1 and Pharmacokinetic studies.<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>Four subjects developed \r\n                              grade 3 neutropenia after dosing with peg-interferon; \r\n                              one each after 0.35 and 0.5 j,rg\/kg~and two subjects \r\n                              after of 0.7 pg\/kg. Reversible myelosuppression \r\n                              was considered dose-limiting toxicity. One subject \r\n                              receiving interferon alfa developed grade 3 neutropenia. \r\n                              The most frequent adverse events reported after \r\n                              administration of peg -interferon were an influenza-like \r\n                              syndrome (46%), injection site reaction (58%), headache \r\n                              (46%), and fatigue\/malaise (23%). All interferon \r\n                              alfa doses were associated with moderate decreases \r\n                              in platelet counts.<strong>\"<br>\r\n                              (5\/7)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>The most frequently reported \r\n                              adverse events after administration of peg-interferon \r\n                              were<\/p>\r\n                            <p>asthenia (48%), headache (52%), and myalgia (23%). \r\n                              Peg-interferon produced elevation in body temperature, \r\n                              elevations in serum levels of effector proteins, \r\n                              and decreases in platelet, white cell and neutrophil \r\n                              counts.<strong>\" (7\/3)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>One serious adverse event \r\n                              (myocardial infarction) occurred 12 hours after \r\n                              dosing in a 76 year old woman. All subjects experienced \r\n                              at least one adverse event including flu-like symptoms, \r\n                              headache, reductions in neutrophil and platelet \r\n                              counts, increases in systolic and diastolic blood \r\n                              pressure, heart rate and body temperature.<strong>\"<br>\r\n                              (10\/2)<\/strong><\/p>\r\n\r\n<p align=\"center\"><strong>This, from the safety outcomes \r\n                        of the Phase 3 study<br>\r\n                        under \"other serious adverse events\":<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>The highest incidence \r\n                              of serious adverse events among all organ systems \r\n                              occurred in the neuropsychiatric category (about \r\n                              2% in each treatment group). Serious adverse events \r\n                              in other body systems occurred at a frequency &lt;1%. \r\n                              The individual types of serious adverse events included: \r\n                              suicide attempt, suicidal ideation, severe depression; \r\n                              relapse of drug addiction\/overdose; nerve palsy \r\n                              (facial, oculomotor); cardiomyopathy, myocardial \r\n                              infarction, retinal ischemia, retinal vein thrombosis, \r\n                              transient ischemic attack, supraventricular arrhythmias, \r\n                              loss of consciousness; neutropenia, infection (pneumonia, \r\n                              abscess); autoimmune thrombocytopenia, hyperthyroidism, \r\n                              rheumatoid arthritis, interstitial nephritis, lupus-like \r\n                              syndrome, aggravated psoriasis; urticaria. Additional \r\n                              details of these events are provided in the narratives \r\n                              of serious adverse events.<strong>\"<br>\r\n                              (27\/6)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong><strong>NARRATIVES \r\n                              OF SERIOUS ADVERSE EVENTS<\/strong><\/p>\r\n                            <p>Selected clinical summaries of serious adverse \r\n                              events are provided below. Deaths are listed first \r\n                              followed by other serious events grouped by organ \r\n                              system. The order in which the organ systems are \r\n                              listed is based on the clinical significance of \r\n                              the adverse events. Psychiatric adverse events were \r\n                              the most frequent and most clinically significant \r\n                              serious adverse events. The clinical manifestations \r\n                              of the most frequent serious adverse events appeared \r\n                              to be similar across treatment groups. The rarer \r\n                              adverse events did not appear to be specific to \r\n                              any treatment group. The clinical descriptions of \r\n                              these events were consistent with those of adverse \r\n                              events previously reported in the literature for \r\n                              interferon alfa and described in the drug label.<\/p>\r\n                            <p><strong>Deaths<\/strong><br>\r\n                              <strong>Suicide:<\/strong> Patient 148 was a 42 year-old \r\n                              woman on PEG-IFN 0.5pg\/kg for 25 weeks who died \r\n                              by self-inflicted gunshot wound. Of note is the \r\n                              lack of history of depression. No symptoms or signs \r\n                              of depression were noted by the patient's physicians.<\/p>\r\n                            <p><strong>Suicide, murder, paranoid reaction in the \r\n                              post-treatment period:<\/strong> Patient 598 was \r\n                              a 41 year-old man on IFN for 1 year and a history \r\n                              of depression, antisocial behavior, and drug abuse.<\/p>\r\n                            <p><strong>Sudden death associated with straining \r\n                              at stool:<\/strong> Patient 406 was a 59 year-old \r\n                              man on IFN for 21 weeks. Myocardial infarction was \r\n                              suspected as cause of death. There were neither \r\n                              history nor symptoms of cardiovascular disease and \r\n                              the study ECG was normal. No postmortem examination \r\n                              was performed.<\/p>\r\n                            <p><strong>Psychiatric Adverse \r\n                              Events<\/strong><br>\r\n                              The narratives of the psychiatric adverse \r\n                              events indicate that suicidal behavior, namely ideation, \r\n                              attempt, or completed suicide, was commonly (but \r\n                              by no means invariably) associated with a previous \r\n                              history of depression or other psychiatric diagnoses. \r\n                              Depression and other psychiatric disorders occurred \r\n                              both during the interferon-treatment period and \r\n                              in the post-treatment period.<\/p>\r\n                            <p>Abuse of illicit drugs or ethanol was reported. \r\n                              Very frequently drug abuse represented a relapse \r\n                              of drug addiction and was often associated with \r\n                              development of depression. Overdoses of illicit \r\n                              drugs were also reported. These events did not appear \r\n                              to be a manifestation of suicidal behavior.<\/p>\r\n                            <p><strong>Suicide attempt:<\/strong> Patient 057 was \r\n                              a 49 year-old woman who completed PEG-IFN 1.5 pg\/kg \r\n                              for 1 year and attempted suicide (venisection and \r\n                              intake of 24 g of acetaminophen) in the post-treatment \r\n                              period. The patient had a history of depression \r\n                              and anxiety.<\/p>\r\n                            <p><strong>Suicide attempt, depression, addiction \r\n                              relapse:<\/strong> Patient 371 was a 33 year-old \r\n                              man who completed treatment with PEG-IFN 1.5 pg\/kg. \r\n                              The suicide attempt occurred in the post-treatment \r\n                              period; depression and addiction relapse were also \r\n                              diagnosed at that time. There was a previous history \r\n                              of suicide attempt, depression, and drug abuse.<\/p>\r\n                            <p><strong>Suicidal gesture, depression, anxiety, \r\n                              agitation:<\/strong> Patient 053 was a 53-year-old \r\n                              man on PEG-IFN 1 pg\/kg for 1 year and a history \r\n                              of depression and drug abuse.<\/p>\r\n                            <p><strong>Suicidal\/ ideation, depression, aggressive \r\n                              reaction:<\/strong> Patient 139 was a 40 year-old \r\n                              man on IFN-alfa-2b for 36 weeks and a history of \r\n                              depression.<\/p>\r\n                            <p><strong>Suicidal ideation, depression aggravated:<\/strong> \r\n                              Patient 824 was a 43 year-old woman on PEG-IFN 0.5 \r\n                              pg\/kg for 1 year and a history of depression.<\/p>\r\n                            <p><strong>Suicidal ideation, depression, addiction \r\n                              relapse:<\/strong> Patient 96 was a 40 year-old woman \r\n                              on PEG-IFN 1.5 pg\/kg for 8 weeks who became depressed \r\n                              with suicidal thoughts and resumed ethanol abuse. \r\n                              Patients had a history of suicidal attempts, depression \r\n                              and alcoholism.<\/p>\r\n                            <p><strong>Suicidal ideation, depression, aggressive \r\n                              moods:<\/strong> Patient 411 was a 29 year-old man, \r\n                              on PEG-IFN 1 pg\/kg for 5 months. There was no previous \r\n                              history of depression.<\/p>\r\n                            <p><strong>Suicidal ideation, depression:<\/strong> \r\n                              Patient 012 was a 39 year-old man. PEG-IFN was discontinued \r\n                              after 42 weeks for severe depression and suicidal \r\n                              thoughts. There was no previous history of depression.<\/p>\r\n                            <p><strong>Suicidal ideation, depression:<\/strong> \r\n                              Patient 465 was a 33 year-old man; PEG-IFN 1 .Opg\/kg \r\n                              was discontinued after 8 months for severe depression \r\n                              and suicidal thoughts. There was no previous history \r\n                              of depression.<\/p>\r\n                            <p><strong>Suicidal ideation, emotional lability, \r\n                              depression:<\/strong> Patient 304 was a 34 year-old \r\n                              woman who was discontinued from PEG-IFN 0.5 yg\/kg \r\n                              after about 10 months due to suicidal ideation. \r\n                              There was no previous history of depression.<\/p>\r\n                            <p><strong>Suicidal ideation:<\/strong> Patient 288 \r\n                              was a 39 year-old woman on PEG-IFN 1.5pg\/kg and \r\n                              no previous history of depression. The event resolved \r\n                              with treatment and IFN was continued.<\/p>\r\n                            <p><strong>Depression:<\/strong> Patient 084 was a \r\n                              37 year-old man on PEG-IFN 0.5 pg\/kg for 9 months \r\n                              and a history of depression and drug abuse.<\/p>\r\n                            <p><strong>Addiction relapse\/overdose:<\/strong> Patient \r\n                              084 following discontinuation of PEG-IFN due to \r\n                              depression was hospitalized for respiratory failure \r\n                              and required assisted ventilation. A drug screen \r\n                              was positive for amphetamine, benzodiazepine, pentobarbital, \r\n                              marijuana and ethanol.<\/p>\r\n                            <p><strong>Depression, drug abuse:<\/strong> Patient \r\n                              086 was a 34 year-old woman who completed PEG-IFN \r\n                              1.5 pg\/kg treatment. Depression developed and was \r\n                              followed by use of illicit drugs. The patient had \r\n                              a history of depression.<\/p>\r\n                            <p><strong>Depression, anxiety, addiction relapse:<\/strong> \r\n                              Patient 024 was a 28 year-old man on PEG-IFN 1.5 \r\n                              pg\/kg for 2 months who became anxious, severely \r\n                              depressed an restarted IV drug abuse.<\/p>\r\n                            <p><strong>Depression:<\/strong> Patient 089 was a \r\n                              59 year-old woman on IFN for 2 months who developed \r\n                              severe depression, fatigue and somnolence; previous \r\n                              history of depression.<\/p>\r\n                            <p><strong>Depression:<\/strong> Patient 638 was a \r\n                              43 year-old man who completed one year of treatment \r\n                              with PEG-IFN 0.5 pg\/kg. Depression began within \r\n                              1 month of treatment and waxed and waned in severity. \r\n                              In the post-treatment period the patient was hospitalized \r\n                              for severe depression.<\/p>\r\n                            <p><strong>Addiction relapse\/overdose, depression, \r\n                              agitation, hypothyroidism:<\/strong> Patient 517 \r\n                              was a 47 year-old man on PEG-IFN 0.5 pg\/kg for 37 \r\n                              weeks. He became depressed, agitated, irritable \r\n                              and overdosed on diazepam (#50 10 mg tabs), hydrocodone \r\n                              and dalmane. He developed hypothyroidism requiring \r\n                              treatment. There was a previous history of depression \r\n                              and drug abuse.<\/p>\r\n                            <p><strong>Substance abuse, injury accidental:<\/strong> \r\n                              Patient 097 was a 47 year-old man who completed \r\n                              PEG-IFN 0.5 pg\/kg treatment. The patient sustained \r\n                              a crush injury with pelvic and rib fractures and \r\n                              bladder injury. During hospitalization for the multiple \r\n                              trauma he developed ethanol withdrawal syndrome.<\/p>\r\n                            <p><strong>Addiction relapse:<\/strong> Patient 107 \r\n                              was a 31 year-old man on IFN for 11 months. The \r\n                              patient had history of drug abuse and depression \r\n                              and was hospitalized for detoxification from benzodiazepines.<\/p>\r\n                            <p><strong>Addiction relapse, overdose:<\/strong> Patient \r\n                              306 was a 35 year-old man completed 1 year of treatment \r\n                              with PEG-IFN 0.5 pg\/kg. He was hospitalized for \r\n                              an episode of loss of consciousness diagnosed as \r\n                              drug abuse and unintended overdose of lorazepam \r\n                              and valoron. There was a history of drug abuse.<\/p>\r\n                            <p><strong>Addiction relapse:<\/strong> Patient 297 \r\n                              a 35 year-old man discontinued IFN treatment after \r\n                              6 months due to relapse of heroin abuse.<\/p>\r\n                            <p><strong>Cardiovascular Adverse \r\n                              Events<\/strong><br>\r\n                              Myocardial infarction, septal, age undetermined, \r\n                              cardiomyopathy, severe depression of left ventricular \r\n                              systolic function: Patient 053 was a 53 year old \r\n                              man on PEG-IFN 1 pg\/kg for 1 year. He became symptomatic \r\n                              and was diagnosed in the post IFN-treatment period.<\/p>\r\n                            <p>Additional evidence of association of ischemic \r\n                              events with IFN consists of one case of myocardial \r\n                              infarction in study C97-058-01 (a PK study), two \r\n                              cases of retinal ischemia in the phase 3 study (see \r\n                              \"Ophthalmic\" narratives below), and post-marketing \r\n                              reports of ischemic colitis associated with interferon \r\n                              alfa-2b.<\/p>\r\n                            <p><strong>Renal Adverse Events<\/strong><br>\r\n                              <strong>Nephrotic syndrome, interstitial \r\n                              nephritis:<\/strong> Patient 087 was a 42 year old \r\n                              man who completed 1 year's treatment with PEG-IFN \r\n                              0.5 f_r.g\/kg. Dramatic increase in body weight and \r\n                              edema were first noted 1 month after the end of \r\n                              IFN treatment. At 3 months post-treatment heavy \r\n                              proteinuria (6g\/24 hrs) was documented with normal \r\n                              urine microscopy, hematology and clinical chemistries. \r\n                              At 4 months post- treatment interstitial nephritis \r\n                              was diagnosed on renal biopsy (focal segmental glomerulosclerosis \r\n                              was included in the differential diagnosis) and \r\n                              corticosteroid treatment was begun for the nephrotic \r\n                              syndrome.<\/p>\r\n                            <p><\/p>\r\n                            <p><strong>Hematologic Adverse \r\n                              Events<\/strong><br>\r\n                              <strong>Autoimmune thrombocytopenia:<\/strong> \r\n                              Patient 0002 was a 58 year-old man who received \r\n                              PEG-IFN 1 .O yglkg for 16 weeks. IFN was stopped \r\n                              when the platelet count dropped to 65x10' from 370x10' \r\n                              at baseline. Other hematology parameters including \r\n                              bone marrow aspirate were normal. Anti-platelet \r\n                              glycoprotein Ilb\/llla was negative at baseline and \r\n                              elevated during treatment. Increased gingival bleeding \r\n                              was the only clinical manifestation of the cytopenia. \r\n                              Platelet count normalized on corticosteroid treatment. \r\n                              After several months of treatment corticosteroids \r\n                              were tapered off without recurrence of thrombocytopenia.<\/p>\r\n                            <p><strong>Autoimmune thrombocytopenia, epistaxis:<\/strong> \r\n                              Patient 157 was a 59 year-old woman who received \r\n                              PEG-IFN 1 .O pg\/kg for 3 months. While on study, \r\n                              Parkinson's disease, gastritis, anxiety, and flu-like \r\n                              syndrome were diagnosed and were treated with biperiden, \r\n                              madopar, famotidine, acetaminophen, and a benzodiazepine. \r\n                              IFN was discontinued due to severe thrombocytopenia \r\n                              (27 xl 0'). Anti-platelet glycoprotein la\/lla and \r\n                              ANA became weakly positive whereas they were negative \r\n                              at baseline. Bone marrow was not examined. Corticosteroid \r\n                              treatment was deemed unnecessary. Three months after \r\n                              discontinuation of IFN the platelet count was 102 \r\n                              xl 0'.<\/p>\r\n                            <p><strong>Ophthalmic Adverse \r\n                              Events<\/strong><br>\r\n                              <strong>Retinal ischemia, decreased visual Acuity, \r\n                              cotton wool spots:<\/strong> Patient 021 was a 58 \r\n                              year-old man on IFN for 3 months. At 4 weeks of \r\n                              treatment he began to complain of decreased vision \r\n                              at night that progressively grew worse. There was \r\n                              no history of diabetes or cardiovascular disease. \r\n                              Ophthalmologic exam at 3 months showed cotton wool \r\n                              spots in the right eye and microvacular ischemia \r\n                              was documented by angiography. IFN was stopped and \r\n                              ophthalmologic changes were reported to be normal \r\n                              8 weeks later.<\/p>\r\n                            <p><strong>Retinal vein thrombosis, vision disorder:<\/strong> \r\n                              Patient 361 was a 48 year-old woman on IFN for 7 \r\n                              months. Evaluation for scotomas in the right eye \r\n                              revealed a thrombosis of the upper temporal pole \r\n                              of the retinal vein with no involvement of the central \r\n                              vein.<\/p>\r\n                            <p><strong>Endocrine Adverse \r\n                              Events<\/strong><br>\r\n                              <strong>Autoimmune thyroiditis mya\/gia,asthenia:<\/strong> \r\n                              Patient 049 was a 30 year-old man, on PEG-INF 1.5 \r\n                              f_rg\/kg for 3 months. He developed asthenia, diarrhea, \r\n                              headaches, myalgia, low TSH, elevated T3 and T4 \r\n                              and positive anti-peroxidase antibodies. IFN was \r\n                              discontinued and carbimazole treatment was begun.<\/p>\r\n                            <p><strong>lnfections<\/strong><br>\r\n                              Because of the bone marrow suppressive effect of \r\n                              interferons alfa, serious infections were reviewed \r\n                              for unusual clinical manifestations or outcomes. \r\n                              The following events were described. Two cases of \r\n                              pneumonias presumed to be bacterial; one case of \r\n                              each of the following: appendicitis; peri-appendiceal \r\n                              abscess with peritonitis; retrouterine abscess in \r\n                              the presence of an IUD; oral abscess following dental \r\n                              extractions; labial abscess associated with controlled \r\n                              diabetes; tonsillitis presumed to be bacterial; \r\n                              erysipelas originating from a wound in the popliteal \r\n                              fossa; aseptic meningitis. The adverse events were \r\n                              not associated with clinically significant decreases \r\n                              in neutrophil counts and patients appeared to recover \r\n                              with treatment. An unusual finding was the presence \r\n                              (in patient 206 on PEG-IFN 0.5 yglkg) of necrotizing \r\n                              epithelioid granulomas in the post-treatment liver \r\n                              biopsy. A diagnosis of mycobacterium infection was \r\n                              considered but was not confirmed.<\/p>\r\n                            <p><strong>Neuroloqic Adverse \r\n                              Events<\/strong><br>\r\n                              Left-sided facial paralysis associated with neutropenia \r\n                              and thrombocytopenia: Patient 022 was a 62 year-old \r\n                              man on PEG-IFN 1 .O pg\/kg for 3 months. Bell's palsy \r\n                              developed while WBC was 0.81 x10' and the platelet \r\n                              count was 81 x10'. Paralysis and cytopenias resolved \r\n                              after discontinuation of IFN. Left-sided facial \r\n                              paralysis: Patient 347 was a 53 year-old woman on \r\n                              PEG-IFN 1 ug\/kg for two months and a history of \r\n                              diabetes. Severe Bell's palsy developed, IFN was \r\n                              stopped and corticosteroids begun; 15 weeks later \r\n                              mild facial drooping remained.<\/p>\r\n                            <p><strong>Oculomotor nerve paralysis, diplopia:<\/strong> \r\n                              Patient 577 was a 48 year-old man with insulin-controlled \r\n                              diabetes. IFN treatment was discontinued after 5 \r\n                              months because of double vision, and drooping left \r\n                              eyelid. Partial oculomotor nerve palsy was attributed \r\n                              to vasculitis caused by diabetes or IFN.<\/p>\r\n                            <p><strong>Hearing loss:<\/strong> Patient 068 was \r\n                              a 36 year-old woman who completed 1 year treatment \r\n                              with PEG-IFN 1.5 yglkg. The patient complained of \r\n                              hearing loss and an audiogram showed a bilateral \r\n                              30% loss of hearing (30 dB in the 1000 and 2000 \r\n                              Hz frequencies) that remained stable on continued \r\n                              IFN treatment.<\/p>\r\n                            <p><strong>Dermatologic Adverse \r\n                              Events<\/strong><br>\r\n                              <strong>Psoriasis aggravated:<\/strong> Patient 149 \r\n                              was a 37 year-old woman on IFN for 3 weeks and a \r\n                              history of mild psoriasis controlled with topical \r\n                              coal extract. The patient developed a severe flare \r\n                              of psoriasis affecting the extremities and associated \r\n                              with arthralgias and eye irritation. IFN was stopped \r\n                              and cyclosporine and calcipotriene were required \r\n                              to control the psoriasis. Exacerbations of psoriasis \r\n                              recurred in the post-treatment period.<\/p>\r\n                            <p><strong>Generalized urticaria:<\/strong> Patient \r\n                              318 was a 54 year-old woman on PEG-IFN 0.5 pg\/kg \r\n                              who developed injection site erythema after the \r\n                              third dose. With the fourth dose the patient developed \r\n                              urticaria that began at the injection site and became \r\n                              generalized. IFN was discontinued and the patient \r\n                              was treated with corticosteroids.<\/p>\r\n                            <p> <strong>Autoimmune Adverse \r\n                              Events<\/strong><br>\r\n                              Systemic lupus erythematosus-like syndrome, Patient \r\n                              327 was a 71 year-old woman who completed a 1 year \r\n                              course of PEG-IFN 1.5 ug\/kg. Six weeks post- treatment \r\n                              the patient developed dyspnea, fever, and thoracic \r\n                              pain. Pericarditis with effusion and pleurisy were \r\n                              diagnosed and diclofenac was administered. GI bleeding \r\n                              occurred, was attributed to diclofenac and was treated \r\n                              with transfusion. A respiratory infection was treated \r\n                              with a cepahalosporin. Serologic testing was positive \r\n                              at high titer for ANA, DS-DNA, TPO, and for thyroid, \r\n                              spleen, thymus, and smooth muscle. No treatment \r\n                              for the autoimmune disorder was considered necessary. \r\n                              To the SLE case should be added the following autoimmune \r\n                              adverse events described above: aggravated psoriasis, \r\n                              thyroiditis, thrombocytopenia, and nephritis. In \r\n                              addition ulcerative colitis (presenting with fever, \r\n                              abdominal pain, and bloody diarrhea) has been associated \r\n                              with interferon alfa by postmarketing adverse event \r\n                              reports.<strong>\"<br>\r\n                              (33\/2-38\/8)<\/strong><\/p>\r\n\r\n <p align=\"center\"><strong>The following sentence states \r\n                        the study's conclusion <br>\r\n                        regarding PEG-Intron's safety.<\/strong><\/p>\r\n                      <p><\/p>\r\n\r\n<p><strong>\"<\/strong>Peg-interferon \r\n                              alfa-2b and interferon alfa-2b cause or aggravate \r\n                              fatal or life-threatening neuropsychiatric, autoimmune, \r\n                              ischemic, and infectious disorders.<strong>\"<br>\r\n                              (42\/5)<\/strong><\/p>\r\n\r\n<p align=\"center\"><strong>Needless to say, they found that \r\n                        patients had to<br>\r\n                        take more medications to deal with the \"adverse events\".<\/strong><\/p>\r\n                      <p><\/p>\r\n\r\n<p><strong>\"<\/strong>During \r\n                              the study treatment period the use of drugs within \r\n                              the following classes increased compared to use \r\n                              at baseline. Use of analgesic\/antipyretic, and anti-inflammatory \r\n                              agents (including NSAIDS) increased roughly 5fold \r\n                              from 10% to 50%; use of antihistaminic drugs also \r\n                              rose five-fold from roughly 5 % to 25% and use of \r\n                              corticosteroids rose approximately 4-fold from 2% \r\n                              at baseline. Use of psychotherapeutic drugs including \r\n                              antidepressants, sedatives and hypnotics, and tranquilizers \r\n                              rose 3-4 fold; around 20-24% of patients received \r\n                              antidepressant drug&amp;-The largest relative increase \r\n                              in drug use occurred for antimicrobial agents whose \r\n                              use increased from l-2% at baseline to up to 14% \r\n                              during the treatment period. The drugs were used \r\n                              as treatment or prophylaxis against the most common \r\n                              adverse events associated with interferons, namely \r\n                              flu-like symptoms, fever, headaches, myalgias, injection \r\n                              site reactions, depression, anxiety\/irritability, \r\n                              and insomnia.<strong>\"<br>\r\n                              (31\/1-2)<\/strong><\/p>\r\n\r\n <p align=\"center\"><strong>PEG-INTRON \r\n                        IS NOT EFFECTIVE<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>In the \r\n                              three lower peg-interferon dose groups (~0.25 pg\/kg) \r\n                              one patient ( l\/18, 5% ) \r\n                              responded to treatment. In the five higher peg-interferon \r\n                              dose groups (0.5 2.0 yg\/kg QW and 0.5 pg\/kg BIW \r\n                              ) eight patients ( 8\/30, \r\n                              27% ) responded to treatment. In each of the \r\n                              five highest dose groups, \r\n                              1-2 patients out of six was a responder; \r\n                              therefore no dose-response trends were observed. \r\n                              In the interferon- treated group 2\/16 patients (12%) \r\n                              responded to treatment.<strong>\"<br>\r\n                              (9\/1)<\/strong><\/p>\r\n\r\n<p align=\"left\">The primary efficacy outcome of the Phase \r\n                        3 study reported response rates between 17% and 24% (see \r\n                        Table 7 on page 20). Of the people they considered responders, \r\n                        about half relapsed and most did so right away.<\/p>\r\n\r\n<p><strong>\"<\/strong>The \r\n                              time to virologic relapse was not different between \r\n                              groups. A large proportion of patients (41-54% across \r\n                              treatment groups) with undetectable serum HCV RNA \r\n                              by the end of 12 months of treatment had detectable \r\n                              HCV RNA by six months after the end of treatment. \r\n                              Virologic relapse occurred primarily during the \r\n                              first four weeks of the post-treatment period (see \r\n                              Table 10).<strong>\"<br>\r\n                              (24\/1)<\/strong><\/p>\r\n\r\n<p><strong>\"<\/strong>Scores \r\n                              for liver inflammation\/necrosis and liver fibrosis \r\n                              were not superior with \r\n                              peg-interferon alfa-2b treatment compared to interferon \r\n                              alfa-2b treatment.<\/p>\r\n                            <p>Time to response to treatment and time to relapse \r\n                              were &nbsp;not superior \r\n                               with peg-interferon alfa-2b treatment compared \r\n                              to interferon alfa-2b treatment.<\/p>\r\n                            <p>&nbsp;Health-Related Quality \r\n                              of Life Scores were not improved in any of \r\n                              the interferon treatment groups either during or \r\n                              after treatment.<strong>\"<br>\r\n                              (40\/5-7)<\/strong><\/p>\r\n\r\n<p>Finally, the researchers found that PEG-Intron was not \r\n                        even as effective as a drug combination that already existed \r\n                        (<em>I am in no way saying that the existing drug choice \r\n                        was a good one either<\/em>).<\/p>\r\n\r\n<p><strong>\"<\/strong>It should \r\n                              be noted that response rates to peg-interferon alfa-2b \r\n                              monotherapy appear to be inferior to those of combination \r\n                              therapy with interferon alfa-2b plus ribavirin.<strong>\" \r\n                              (43\/2)<\/strong><\/p>\r\n\r\n <p>Perhaps the most important conclusion the researchers \r\n                        reached was from the study they titled \"Health-Related \r\n                        Quality of Life\" (<em>Phase 3 Study, Secondary Efficacy \r\n                        Outcomes<\/em>). This one hit closest to home for me because, \r\n                        well, what else is there other than quality of life? They \r\n                        assessed the subjects' qualities of life based on \"...health \r\n                        physical functioning, role physical, bodily pain, general \r\n                        health perceptions, vitality, social functioning, role \r\n                        emotional, and general mental health\".<\/p>\r\n\r\n<p><strong>\"<\/strong>All \r\n                              the scores in all the groups deteriorated during \r\n                              the treatment period and tended to return to baseline \r\n                              in the post-treatment period.<strong>\"<br>\r\n                              (24\/4)<\/strong><\/p>\r\n\r\n <p>In other words, each subject's quality of life became \r\n                        worse during the PEG-Intron therapy, then returned to \r\n                        the same as before (<em>not better<\/em>) once the therapy \r\n                        ended. PEG-Intron makes your life miserable for the time \r\n                        period you are on it then no better than before once you \r\n                        stop. This is not for me. I'm into life.<\/p>\r\n\r\n<p><strong>After reading 43 pages of evidence, \r\n                              in Schering's own words,<\/strong> <\/p>\r\n                            <p><strong> that PEG-Intron \r\n                              is not effective and not safe,<\/strong><\/p>\r\n                            <p><strong> that few respond \r\n                              and most relapse,<\/strong> <\/p>\r\n                            <p align=\"left\"><strong> that  \r\n                              it has a laundry list of intolerable side effects<\/strong><br>\r\n                              <strong>(<em>most of them psychiatric<\/em>),<\/strong><\/p>\r\n                            <p align=\"left\"><strong>that  \r\n                              the side effects don't always resolve<\/strong><br>\r\n                              after the treatment is stopped,<\/p>\r\n                            <p align=\"left\"><strong> that  \r\n                              the therapy doesn't ever improve the patients' quality \r\n                              of life (<em>not during the treatment, not \r\n                              after the treatment<\/em>),<\/strong><\/p>\r\n\r\n<p align=\"center\"><strong> I wondered \r\n                        if the people who approved it<br>\r\n                        read the same review as I did.<\/strong><\/p>\r\n                      <p align=\"center\"><strong>But when I went to the CBER's \r\n                        web site it became a little clearer;<\/strong><br>\r\n                        it seems that when they calculate a new drug's safety<br>\r\n                        verses its \"reasonable risks\",<br>\r\n                        <strong>one of their main considerations is the \"alternatives \r\n                        available\".<\/strong><\/p>\r\n                      <p align=\"center\">With no alternatives available that they \r\n                        recognize,<br>\r\n                        PEG-Intron was a shoo-in.<\/p>\r\n                      <p align=\"center\"><strong>Peg-Intron \r\n                        Biologic License Application<\/strong> (.pdf)<\/p>\n","contact":"","link":"http:\/\/www.hepatitiscfree.com","address":"","phone":"","parent_id":0,"mime_type":"text\/html","summary":"I have been trying for years to expose the truth behind PEG-Intron therapy, its horrible side effects, its ineffectiveness, and the real reason the drug manufacturer altered Interferon to create it. ","numcomment":0,"fileurl":"\/uploads\/","filesize":null,"article_url":"\/news\/2003\/04\/53183.php"},"attachments":[],"comments":[]}